Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 9/20 | 0.35 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.35 |
| ▸ | MET | P08581 | 2/20 | 0.35 |
| ▸ | FUBP1 | Q96AE4 | 1/20 | 0.35 |
| ▸ | FYN | P06241 | 2/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL956154 | 0.81 | FFAR1 (0.40) | ABCB1ABCG2METFUBP1FYN | |
| SCHEMBL955471 | 0.81 | DPP4 (0.38) | ABCB1ABCG2METFUBP1FYN | |
| SCHEMBL959357 | 0.81 | DPP4 (0.41) | ABCB1ABCG2METFUBP1ADORA2A | |
| SCHEMBL956506 | 0.78 | ABCB1 (0.44) | ABCB1ABCG2METFUBP1ADORA2A | |
| SCHEMBL956593 | 0.78 | DPP4 (0.41) | ABCB1ABCG2METFUBP1FYN | |
| SCHEMBL956372 | 0.78 | FUBP1 (0.39) | ABCB1ABCG2METFUBP1FYN | |
| SCHEMBL954712 | 0.77 | POLB (0.43) | ABCB1ABCG2METFUBP1ADORA2A | |
| SCHEMBL957323 | 0.75 | FFAR1 (0.39) | ABCB1ABCG2METFUBP1FYN | |
| SCHEMBL956808 | 0.74 | DPP4 (0.42) | ABCB1ABCG2METFUBP1FYN | |
| SCHEMBL959394 | 0.73 | ABCB1 (0.44) | ABCB1ABCG2METFUBP1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | NOVARTIS AG (CH) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009429-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF CXCR2 | CXCR2, CXCR1, CXCR3 | ABCB1 649/4885ABCG2 304/4885MET 1035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.